Patient Centered Care: It’s All About the Partnerships

SPONSORED CONTENT

If you work for an organization specializing in HIV care and/or prevention, you no doubt work incredibly hard to ensure you provide care that is patient-focused in an environment that is affirming and welcoming. I can imagine on your clinic’s walls there are informational posters about the importance of preventative tools like PrEP. On Facebook and Twitter, you might post about the importance of U=U and breaking down the barriers caused by decades of shame and stigma. You are also likely surrounded by health care providers and staff who understand the unique experiences of LGBTQIA+ patients and who treat every single person with care and respect. In your work in HIV prevention or with individuals living with HIV, you understand how important it is to ensure that every single touchpoint in a patient’s care journey aligns with your overall mission. You make every effort to ensure that you meet the specific needs of your community and that each patient feels

Read More »

News Alert: Judge Denies Sanofi Stay Against 340B ADR Proceedings, as Stakeholders Brace for Coming Whirlwind of Crucial Decisions in 340B Cases

A federal district judge yesterday denied Sanofi's emergency request for a stay against 340B ADR proceedings, in part because she said she will rule in Sanofi's 340B contract pharmacy lawsuit on or before Nov. 5.

A federal district judge in New Jersey has denied drug manufacturer Sanofi’s emergency motion for a stay against 340B administrative dispute resolution (ADR) proceedings—in part because she said she will hand down her decision in Sanofi’s 340B contract pharmacy lawsuit

Read More »

In Important Development, HHS Close to Rescinding Trump-era Rule that Undercuts its Sub-Regulatory Power

HHS is poised to rescind Trump administration regulations that have added to doubt about the authority of HHS guidance documents, including for 340B.

The U.S. Health and Human Services Department (HHS) is poised to rescind Trump administration regulations that have added to doubt about the authority of HHS guidance documents, including those for the 340B program.

During the Trump administration, the U.S Health

Read More »

A Closer Look at Critical Court Hearing on 340B Contract Pharmacy Legality

A federal district court in Washington, D.C., heard arguments this week in Novartis and United Therapeutics' 340B contract pharmacy lawsuits.

U.S. District Judge Dabney Friedrich all but told the federal government during a court hearing in Washington, D.C., on Tuesday she rejects its basic argument that the plain text of the 340B statute requires drug manufacturers to honor 340B purchases

Read More »

Feds Oppose Sanofi’s Request for Emergency Protection Against 340B ADR Proceedings

The federal government yesterday opposed Sanofi's request to a judge to grant it emergency protection from 340B dispute resolution proceedings.

The federal government yesterday asked a federal district judge to deny drug manufacturer Sanofi’s request for emergency protection from being brought before a 340B administrative dispute resolution panel.

Sanofi asked the judge for an emergency stay last week. The

Read More »

Drug Manufacturers May Seek Orphan Designations to Avoid Paying 340B Discounts, HHS OIG Concludes

The 340B orphan drug exclusion incentivizes manufacturers to get orphan designations for drugs approved to treat common diseases or conditions, a new government report says.

The ban on 340B discounts on orphan drugs for rural and free-standing cancer hospitals may give drug companies a powerful incentive “to seek orphan designation for drugs approved to treat common diseases or conditions,” the U.S. Health and Human Services

Read More »

340B Coalition Says It Will Hold 2022 Winter Conference in-Person

The 340B Coalition is holding its 2022 winter conference in person in San Diego.

The 340B Coalition announced Tuesday that its annual winter conference will be held in person Jan. 31 to Feb. 2, 2022, in San Diego. Its last, pre-pandemic in-person conference was Feb. 10-12, 2020, also in San Diego.

Apexus, the 340B

Read More »

Why Contracting with Specialty Pharmacies Could Seriously Grow Your 340B Referral Script Savings

SPONSORED CONTENT by Hannah Drake, Senior Director of Marketing, par8o

340B covered entities strive to ensure they are getting the maximum benefit out of the 340B program in order to help fund services for vulnerable patient populations. For health centers, this means setting up a robust contract pharmacy network.

Surprisingly, more than 70% of par8o’s 340B Referral Capture clients did not have a specialty pharmacy as part of its contract pharmacy network before partnering with par8o. For CEs that include referral scripts in their 340B programs, however, making sure that the contract pharmacy network includes a specialty pharmacy can be key to maximizing valuable 340B opportunity. 

Why Do Health Centers Need Specialty Contract Pharmacies?

Specialty pharmacies tend to dispense drugs that are both high-cost and high-touch, meaning they are part of or require complex therapeutic regimens for diseases that require more comprehensive patient care, such as hepatitis, cancer, HIV, rheumatoid arthritis and Crohn’s disease. Retail pharmacies generally dispense

Read More »

Judge Expresses Doubt About Government’s Position During Arguments in Novartis and United Therapeutics’ 340B Contract Pharmacy Lawsuits

U.S. District Judge Dabney Friedrich said today she agreed with another federal judge that the plain text of the 340B statute "doesn't speak" to contract pharmacy.

A federal district judge said today she “has a hard time following” the federal government’s argument that the 340B statute requires drug manufacturers to honor covered entities’ drug purchases no matter how entities choose to distribute the medicines.

“It seems

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report